Full View

Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2

D Watterson, DK Wijesundara… - Clinical & …, 2021 - Wiley Online Library
Objectives Efforts to develop and deploy effective vaccines against severe acute respiratory
syndrome coronavirus 2 (SARS‐CoV‐2) continue at pace. Here, we describe rational …
被引用次数：56 相关文章
[PDF] scienceopen.com

[PDF][PDF] Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2

scienceopen.com
Objectives. Efforts to develop and deploy effective vaccines against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) continue at pace. Here, we describe rational antigen …
[PDF] unimelb.edu.au

[PDF][PDF] Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2

minerva-access.unimelb.edu.au
Objectives. Efforts to develop and deploy effective vaccines against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) continue at pace. Here, we describe rational antigen …

[引用][C] Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2

D Watterson, DK Wijesundara… - Clinical & …, 2021 - espace.library.uq.edu.au
Objectives: Efforts to develop and deploy effective vaccines against severe acute respiratory
syndrome coronavirus 2 (SARS‐CoV‐2) continue at pace. Here, we describe rational …

Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2.

D Watterson, DK Wijesundara… - Clinical & …, 2021 - search.ebscohost.com
Objectives: Efforts to develop and deploy effective vaccines against severe acute respiratory
syndrome coronavirus 2 (SARS‐CoV‐2) continue at pace. Here, we describe rational …
[HTML] nih.gov

[HTML][HTML] Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2

D Watterson, DK Wijesundara, N Modhiran… - Clinical & …, 2021 - ncbi.nlm.nih.gov
Objectives Efforts to develop and deploy effective vaccines against severe acute respiratory
syndrome coronavirus 2 (SARS‐CoV‐2) continue at pace. Here, we describe rational …
[PDF] researchgate.net

[PDF][PDF] Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2

researchgate.net
Objectives. Efforts to develop and deploy effective vaccines against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) continue at pace. Here, we describe rational antigen …

Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2

D Watterson, DK Wijesundara… - Clinical & …, 2021 - search.proquest.com
Objectives Efforts to develop and deploy effective vaccines against severe acute respiratory
syndrome coronavirus 2 (SARS‐CoV‐2) continue at pace. Here, we describe rational …

Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2

D Watterson, DK Wijesundara… - Clinical & …, 2021 - pubmed.ncbi.nlm.nih.gov
Objectives Efforts to develop and deploy effective vaccines against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) continue at pace. Here, we describe rational antigen …

Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2.

D Watterson, DK Wijesundara, N Modhiran… - Clinical & …, 2021 - europepmc.org
Objectives Efforts to develop and deploy effective vaccines against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) continue at pace. Here, we describe rational antigen …